Goldman Sachs Group Inc. Has $770,000 Stock Holdings in Electromed, Inc. $ELMD

Goldman Sachs Group Inc. raised its stake in shares of Electromed, Inc. (NYSE:ELMD) by 9.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 32,281 shares of the company’s stock after purchasing an additional 2,672 shares during the quarter. Goldman Sachs Group Inc.’s holdings in Electromed were worth $770,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. State of Wyoming bought a new position in shares of Electromed during the 1st quarter worth approximately $48,000. Bank of America Corp DE lifted its holdings in shares of Electromed by 179.2% during the fourth quarter. Bank of America Corp DE now owns 4,004 shares of the company’s stock valued at $118,000 after acquiring an additional 2,570 shares during the period. Quantbot Technologies LP boosted its stake in shares of Electromed by 57.7% in the 1st quarter. Quantbot Technologies LP now owns 5,301 shares of the company’s stock valued at $126,000 after purchasing an additional 1,939 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Electromed by 557.0% in the 1st quarter. Russell Investments Group Ltd. now owns 7,969 shares of the company’s stock worth $186,000 after purchasing an additional 6,756 shares during the last quarter. Finally, Two Sigma Advisers LP acquired a new stake in shares of Electromed during the 4th quarter worth about $219,000. 40.82% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Electromed news, Director Andrew Summers sold 3,153 shares of the company’s stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $24.42, for a total value of $76,996.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 14.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ELMD. Loop Capital set a $36.00 price target on shares of Electromed in a research report on Wednesday, August 27th. Lake Street Capital assumed coverage on Electromed in a report on Wednesday, August 27th. They issued a “buy” rating and a $36.00 target price on the stock. Finally, Roth Capital raised their price target on Electromed from $29.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, August 27th. One research analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $36.25.

Electromed Trading Down 4.0%

Electromed stock opened at $23.88 on Wednesday. The firm has a market capitalization of $199.37 million, a P/E ratio of 31.84 and a beta of 0.54. The business has a 50-day moving average of $21.22 and a 200-day moving average of $21.72. Electromed, Inc. has a 1 year low of $17.73 and a 1 year high of $35.56.

About Electromed

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.